MFMelina Farshbafnadi

Melina Farshbafnadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Melina Farshbafnadi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Revealing Sex Disparities in the Burden of Diarrheal Diseases Among Children Under 5: Global and Asian Trends and Projections, 1990–2050 – A Population‐Based Observational Analysis Using GBD 2021 Data

    by Maedeh Amini, Paria Dehesh, Melina Farshbafnadi, Elaheh Dehghani

    Background: Although the global burden of diarrheal diseases (DDs) among children under 5 years of age has declined substantially over recent decades, sex‐specific disparities and regional heterogeneity across Asia—particularly regarding non‐fatal outcomes—remain insufficiently characterized. This study investigated long‐term global and Asian trends in the burden of DDs by sex and projected future patterns to inform equitable child health strategies. Methods: Sex‐disaggregated data on incidence, prevalence, mortality, and disability‐adjusted life years (DALYs) among children under 5 years of age were obtained from the Global Burden of Disease 2021 Study. Temporal trends were evaluated using estimated annual percentage changes. For Asian countries, three‐level hierarchical linear mixed‐effects models were used to identify factors associated with disease burden. In addition, autoregressive integrated moving average models were applied to forecast sex‐specific trends over the next 30 years. Results: Between 1990 and 2021, the burden of DDs declined substantially among both males and females across all outcome measures, although males consistently experienced higher DALYs and mortality. Across Asia, considerable regional heterogeneity was observed. The largest declines occurred in Southeast Asia and South Asia, whereas the smallest declines were observed in High‐income Asia Pacific. Incidence and prevalence rates decreased in most regions but plateaued or increased slightly in East Asia and High‐income Asia Pacific. Multilevel analyses demonstrated significantly higher DALYs and mortality among males and revealed strong inverse associations between the Sociodemographic Index and the burden of DDs. Projections to 2050 indicate continued declines globally and across most Asian subregions; however, the greatest absolute burden is expected to remain in South and Southeast Asia, with relatively limited progress projected for Central Asia and High‐income Asia Pacific. Conclusions: Despite substantial progress in reducing the burden of DDs among children under 5 years of age, marked sex disparities and regional inequalities persist across Asia. Targeted, sex‐specific interventions—particularly in South Asia and Southeast Asia—remain essential to accelerate progress and promote equitable child health outcomes.

  • Open Access

    A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment

    by Nazila Heidari, Rad Ghannadzadeh Kermani Pour, Melina Farshbafnadi, Amirhossein Heidari, Yekta Ghane

    Background: Dissecting cellulitis of the scalp (DCS) is a type of neutrophilic scarring alopecia identified by the development of folliculitis with clusters of perifollicular pustules and then progresses to abscesses and intercommunicating sinus formation. In the absence of evidence-based guidelines, the treatment of DCS remains a therapeutic challenge. Our study aimed to assess the safety and efficacy of biologics, including tumor necrosis factor-α (TNF-α) blockers, anti-interleukins (ILs), and small molecule inhibitors, including Janus kinase (JAK) inhibitors and phosphodiesterase inhibitors in treating DCS. Methods: PubMed/Medline, Scopus, and Ovid Embase databases were systematically searched until February 4th, 2024. Study selection was restricted to case reports, case series, cohort studies, and clinical trials published in English-language. NIH and Murad et al.’s quality assessment tools were utilized for critical appraisal. Results: A total of 34 articles involving 81 patients met the inclusion criteria. The immunomodulators studied for the treatment of DCS include adalimumab, infliximab, certolizumab pegol, ustekinumab, secukinumab, guselkumab, risankizumab, tildrakizumab, apremilast, upadacitinib, and baricitinib. Our findings implied that TNF-α blockers and IL inhibitors were associated with clinical improvement in most individuals with moderate-to-severe DCS, especially in those who had failed earlier treatments. Moreover, certolizumab pegol could be a safe option for DCS in pregnancy. In addition, the prescription of small molecule inhibitors, including JAK inhibitors and apremilast in DCS patients, demonstrated a significant amelioration in DCS symptoms with a desirable safety profile. Nevertheless, the available data was limited, warranting further investigation. Besides, all aforementioned immunomodulators are still debated for their effectiveness on hair regrowth and reversing the scarring process. Conclusions: The application of immunomodulators in treating DCS was associated with satisfactory outcomes, although there is still a need to assess the long-term safety and effectiveness of these therapeutic agents in preventing disease progression and new flare-ups.


  • Open Access

    National and Subnational Burden of Cardiovascular Diseases in Iran from 1990 to 2021: Results from Global Burden of Diseases 2021 study

    by Mahsa Heidari-Foroozan, Melina Farshbafnadi, Ali Golestani, Sepehr Younesian, Hosein Jafary, Mohammad-Mahdi Rashidi, Ozra Tabatabaei-Malazy, Nazila Rezaei, Mostafa Moghimi Kheirabady, Arash Bagherian Ghotbi, et al.

    Introduction: In 2021, cardiovascular diseases (CVD) caused around 20.5 million deaths worldwide, making them a major health concern. Methods: Incidence, prevalence, death, years of life lost (YLL), years lived with disability (YLD), and disability-adjusted life years (DALYs) were the burden measures that were assessed. All measures are reported as both all-age numbers and age-standardized rates (ASR) with 95% uncertainty intervals (UI). Decomposition analysis was conducted on CVD incidence. Results: From 1990 to 2021, all-age CVD prevalence in Iran increased by 182.6% (2.9 to 8.3 million cases), with males consistently showing higher age-standardized prevalence rates (ASPR) than females (11,350 vs. 9,431 per 100,000 in 2021). ASPR remained stable nationally (9,956 to 10,386 per 100,000), peaking in adults ≥80 years. Incident cases rose by 159.6% (0.36 to 0.92 million), driven by population growth (49.5%) and aging (136.2%), while age-standardized incidence rates (ASIR) declined by 28.3% (1,337 to 1,197 per 100,000); with males (1,336) exhibiting higher rates than females (1,060) in 2021. All age deaths doubled (86,527 to 169,582) during this period, but age-standardized death rates (ASDR) decreased substantially by 42.97% (446 to 255 per 100,000). DALYs increased by 53.7% (2.4 to 3.7 million), though age-standardized DALY rates dropped 45.3% (9,096 to 4,977 per 100,000), dominated by ischemic heart disease (2,731 ASR) and stroke (1,229 ASR). High systolic blood pressure, dietary risks, and LDL cholesterol remained the leading contributors to DALYs nationwide. Conclusion: Iran’s rising CVD burden demands prioritizing cardiac care infrastructure in underserved provinces like Golestan, enforcing sodium reduction policies aligned with Iran’s existing trans-fat regulations, and integrating sex-specific programs such as tobacco control for males and community hypertension screening for women are critical. Multisectoral collaboration, including urban design promoting physical activity and subsidies for whole grains, must address provincial inequities exacerbated by Iran’s aging population and dietary risks.


  • Open Access

    Microfluidic devices for detection of RNA viruses

    by Arefeh Basiri, Arash Heidari, Melina Farshbaf Nadi, Mohammad Taha Pahlevan Fallahy, Sasan Salehi Nezamabadi, Mohammadreza Sedighi, Amene Saghazadeh, Nima Rezaei

    Summary: There is a long way to go before the coronavirus disease 2019 (Covid‐19) outbreak comes under control. qRT‐PCR is currently used for the detection of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the causative agent of Covid‐19, but it is expensive, time‐consuming, and not as sensitive as it should be. Finding a rapid, easy‐to‐use, and cheap diagnostic method is necessary to help control the current outbreak. Microfluidic systems provide a platform for many diagnostic tests, including RT‐PCR, RT‐LAMP, nested‐PCR, nucleic acid hybridization, ELISA, fluorescence‐Based Assays, rolling circle amplification, aptamers, sample preparation multiplexer (SPM), Porous Silicon Nanowire Forest, silica sol‐gel coating/bonding, and CRISPR. They promise faster, cheaper, and easy‐to‐use methods with higher sensitivity, so microfluidic devices have a high potential to be an alternative method for the detection of viral RNA. These devices have previously been used to detect RNA viruses such as H1N1, Zika, HAV, HIV, and norovirus, with acceptable results. This paper provides an overview of microfluidic systems as diagnostic methods for RNA viruses with a focus on SARS‐CoV‐2.